{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:03:14Z","timestamp":1784685794171,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04421-z","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T06:27:22Z","timestamp":1779604042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1357-1120","authenticated-orcid":false,"given":"Karim","family":"Amrane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Campedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Moinard-Butot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Gout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Mahammedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostefa","family":"Bennamoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tressie","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Etienne","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Pouessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Roulleaux-Dugage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Cancel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Flechon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Huillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Abbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Borchiellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Doublet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"La\u00ebtitia","family":"Augusto-Pelegrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elouen","family":"Boughalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"key":"4421_CR1","unstructured":"Cancer (IARC) TIA for R on Global Cancer Observatory. https:\/\/gco.iarc.fr\/. Accessed 2 Jul 2025"},{"key":"4421_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100661","volume":"33","author":"E Yu","year":"2022","unstructured":"Yu E, Belay S, Li W, Aragon-Ching JB (2022) Non-urothelial and urothelial variants of bladder cancer. Cancer Treat Res Commun 33:100661. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100661","journal-title":"Cancer Treat Res Commun"},{"key":"4421_CR3","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.21037\/tcr-20-2169","volume":"9","author":"AJ Black","year":"2020","unstructured":"Black AJ, Black PC (2020) Variant histology in bladder cancer: diagnostic and clinical implications. Transl Cancer Res 9:6565\u20136575. https:\/\/doi.org\/10.21037\/tcr-20-2169","journal-title":"Transl Cancer Res"},{"key":"4421_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","volume":"6","author":"N Lobo","year":"2020","unstructured":"Lobo N, Shariat SF, Guo CC et al (2020) What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus 6:653\u2013663. https:\/\/doi.org\/10.1016\/j.euf.2019.09.003","journal-title":"Eur Urol Focus"},{"key":"4421_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2298\/SARH1110693D","volume":"139","author":"I Damjanov","year":"2011","unstructured":"Damjanov I, Golubovic M (2011) Histopathology of urinary bladder carcinoma: Less common variants. Srp Arh Celok Lek 139:693\u2013699. https:\/\/doi.org\/10.2298\/SARH1110693D","journal-title":"Srp Arh Celok Lek"},{"key":"4421_CR6","doi-asserted-by":"crossref","unstructured":"Kim YA, Moon KC (2018) Histological Classification of Bladder Tumors. In: Bladder Cancer. Elsevier Inc., pp 147\u2013180","DOI":"10.1016\/B978-0-12-809939-1.00011-4"},{"key":"4421_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/his.13719","volume":"74","author":"S Park","year":"2019","unstructured":"Park S, Reuter VE, Hansel DE (2019) Non-urothelial carcinomas of the bladder. Histopathology 74:97\u2013111. https:\/\/doi.org\/10.1111\/his.13719","journal-title":"Histopathology"},{"key":"4421_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.671969","volume":"11","author":"N Epaillard","year":"2021","unstructured":"Epaillard N, Parent P, Loriot Y et al (2021) Treatments outcomes in histological variants and non-urothelial bladder cancer: Results of a multicenter retrospective study. Front Oncol 11:671969. https:\/\/doi.org\/10.3389\/fonc.2021.671969","journal-title":"Front Oncol"},{"key":"4421_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.juro.2015.02.2941","volume":"194","author":"B Wang","year":"2015","unstructured":"Wang B, Wu S, Zeng H et al (2015) CD103+ tumor infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J Urol 194:556\u2013562. https:\/\/doi.org\/10.1016\/j.juro.2015.02.2941","journal-title":"J Urol"},{"key":"4421_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.euo.2019.12.002","volume":"4","author":"J Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits J, Choi W, Pal S et al (2021) Urothelial cancers with small cell variant histology have confirmed high tumor mutational burden, frequent TP53 and RB mutations, and a unique gene expression profile. Eur Urol Oncol 4:297\u2013300. https:\/\/doi.org\/10.1016\/j.euo.2019.12.002","journal-title":"Eur Urol Oncol"},{"key":"4421_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040910","volume":"10","author":"J-H Chung","year":"2022","unstructured":"Chung J-H, Lee C-U, Lee D-H, Song W (2022) Expression and prognostic implication of PD-L1 in patients with urothelial carcinoma with variant histology (squamous differentiation or micropapillary) undergoing radical cystectomy. Biomedicines 10:910. https:\/\/doi.org\/10.3390\/biomedicines10040910","journal-title":"Biomedicines"},{"key":"4421_CR12","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of Non\u2013Small-Cell Lung Cancer. N Engl J Med 372:2018\u20132028. https:\/\/doi.org\/10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"key":"4421_CR13","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 377:1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"4421_CR14","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA et al (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29:3044\u20133060. https:\/\/doi.org\/10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"4421_CR15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"key":"4421_CR16","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383:1218\u20131230. https:\/\/doi.org\/10.1056\/NEJMoa2002788","journal-title":"N Engl J Med"},{"key":"4421_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S et al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390:875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"key":"4421_CR18","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T et al (2023) Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med 389:1778\u20131789. https:\/\/doi.org\/10.1056\/NEJMoa2309863","journal-title":"N Engl J Med"},{"key":"4421_CR19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, Bellmunt J, Vaughn DJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30:970\u2013976. https:\/\/doi.org\/10.1093\/annonc\/mdz127","journal-title":"Ann Oncol"},{"key":"4421_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.536","author":"TB Powles","year":"2025","unstructured":"Powles TB, Van der Heijden MS, Loriot Y et al (2025) Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.536","journal-title":"Ann Oncol"},{"key":"4421_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","volume":"34","author":"AV Balar","year":"2023","unstructured":"Balar AV, Castellano DE, Grivas P et al (2023) Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol 34:289\u2013299. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.012","journal-title":"Ann Oncol"},{"key":"4421_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/iju5.12334","volume":"4","author":"K Fukuta","year":"2021","unstructured":"Fukuta K, Izaki H, Shiozaki K et al (2021) Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma. IJU Case Rep 4:310\u2013313. https:\/\/doi.org\/10.1002\/iju5.12334","journal-title":"IJU Case Rep"},{"key":"4421_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.eururo.2025.04.008","volume":"88","author":"CE Chu","year":"2025","unstructured":"Chu CE, Chen Z, Whiting K et al (2025) Clinical outcomes, genomic heterogeneity, and therapeutic considerations across histologic subtypes of urothelial carcinoma. Eur Urol 88:472\u2013481. https:\/\/doi.org\/10.1016\/j.eururo.2025.04.008","journal-title":"Eur Urol"},{"key":"4421_CR24","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.2024.42.4_suppl.678","volume":"42","author":"D Lynn","year":"2024","unstructured":"Lynn D, Dawsey S, Patgunarajah U et al (2024) Effect of neutrophil to lymphocyte ratio (NLR) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in real-world setting. J Clin Oncol 42:678\u2013678. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.678","journal-title":"J Clin Oncol"},{"key":"4421_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00262-021-03000-8","volume":"71","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T, Ito K, Kojima T et al (2021) Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR. Cancer Immunol Immunother 71:461\u2013471. https:\/\/doi.org\/10.1007\/s00262-021-03000-8","journal-title":"Cancer Immunol Immunother"},{"key":"4421_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.euo.2024.09.014","volume":"8","author":"P Barth\u00e9l\u00e9my","year":"2025","unstructured":"Barth\u00e9l\u00e9my P, Thibault C, Fl\u00e9chon A et al (2025) Real-world study of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in France: overall results from the noninterventional AVENANCE study and analysis of outcomes by second-line treatment. Eur Urol Oncol 8:407\u2013416. https:\/\/doi.org\/10.1016\/j.euo.2024.09.014","journal-title":"Eur Urol Oncol"},{"key":"4421_CR27","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1200\/JCO.2025.43.16_suppl.4575","volume":"43","author":"A Abdelnaser","year":"2025","unstructured":"Abdelnaser A, Shavakhi M, Ravi A et al (2025) Impact of histological subtypes in patients receiving first-line treatment with enfortumab vedotin\/pembrolizumab in advanced metastatic urothelial cancer. J Clin Oncol 43:4575\u20134575. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4575","journal-title":"J Clin Oncol"},{"key":"4421_CR28","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.21873\/anticanres.15851","volume":"42","author":"S Inoue","year":"2022","unstructured":"Inoue S, Sassa N, Kawanishi H et al (2022) Impact of histological variants on clinical responses to Pembrolizumab in patients with metastatic urothelial cancer. Anticancer Res 42:3627\u20133636. https:\/\/doi.org\/10.21873\/anticanres.15851","journal-title":"Anticancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04421-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04421-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04421-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:47:15Z","timestamp":1784684835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04421-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4421"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04421-z","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KA received honoraria from Astellas, MSD, BMS, and Pfizer. The other authors have no conflicts of interest to declare. MG has no conflicts of interest to declare CD reports occasional engagements for Astellas, BMS, Janssen, MSD and Pfizer FMB has no conflicts of interest to declare HM declares receiving payment or honorarium from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Ipsen, Janssen, Merck, MSD, Novartis and Pfizer; travel or other expenses from AstraZeneca, Novartis, Pfizer, Roche; and acting on a scientific steering committee for Curium MB: Financial Interests, Invited Speaker: Janssen, AstraZeneca, Ipsen, Astellas TH has no conflicts of interest to declare PEG has no conflicts of interest to declare DP serves as a consultant\/receives honorarium\/travel reimbursements from Astellas, Astra Zeneca, Bayer, BMS, MSD, Pfizer MRD has no conflicts of interest to declare CT: Amgen, AstraZenenca, AdaCap, Astellas, Bayer, BMS, Gilead, Ipsen, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, Sanofi, Seagen MC has no conflicts of interest to declare AF declares receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Astellas, AstraZeneca, AAA, Bayer, Janssen, Novartis, and Pfizer; and support for attending meetings and\/or travel from Astellas, AstraZeneca, AAA, Bayer, Janssen, Novartis, and Pfizer OH serves as a consultant\/receives honorarium\/travel reimbursements from serves as a consultant\/receives honorarium\/travel reimbursements from ADACAP, Astra Zeneca, Bayer, BMS, Curium, Eisai, Ipsen, Johnson & Jphnson, Merck, MSD, Novartis, Pfizer, Sanofi BA has received research Grants from MSD Avenir; consulting fees or honoraria from Novartis, Astellas, Sanofi, AstraZeneca, BMS, and MSD; and travel accommodation form Janssen, MSD, Pfizer, IPSEN Pharma, Bayer, and Takeda. DB has received honoraria for advisory boards or lectures from Accord Healthcare, Astellas, Astra-Zeneca, Bayer, BMS, Ipsen, Janssen, Merck, Novartis, Pfizer. LD has no conflicts of interest to declare LAP has no conflicts of interest to declare EB has no conflicts of interest to declare PC serves as a consultant\/receives honorarium\/travel reimbursements from Amgen, Astellas, Astra Zeneca, Bayer, BMS, Eisai, Ipsen, Johnson & Jphnson, Merck, MSD, Pfizer LC serves as a consultant\/receives honorarium\/travel reimbursements from Amgen, Astellas, Astra Zeneca, Bayer, BMS, Eisai, Ipsen, Johnson & Jphnson, Merck, MSD, Pfizer P.B. received advisory\/consulting fees from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Ipsen, Merck, MSD, Pfizer, and Novartis\/AdaCaP, research-funding support from Ipsen, AstraZeneca, and BMS.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study conformed to the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines. A local independent Ethics Committee (2023-CF025) approved it.","order":2,"name":"Ethics","label":"Ethical approval.","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"191"}}